Pulsatile perfusion is increasingly being used to preserve kidneys harvested from non-standard-criteria donors. Indeed, retrospective analyses have shown that machine preservation is associated with reduced rates of delayed graft function. However, well-designed prospective clinical trials are needed to evaluate its impact on organ discard, rejection, long-term graft function, and cost.
In the 1960s, all deceased donor kidneys were procured after cardiac arrest. 1 Pulsatile preservation (perfusion) was implemented to reduce the resulting emergency by limiting the cold ischaemia time to a few hours. Two major events limited progress in pulsatile perfusion research. Firstly, the Ad Hoc Committee of Harvard Medical School proposed a neurological definition of death in 1968, requiring a number of criteria to be fulfilled. 2 The definition of brain death is widely accepted in most Western countries; however, some controversy remains regarding the specific criteria. 3 Despite the controversy, this policy allows for the recovery of organs with minimal warm ischaemia and has contributed to the success of organ transplantation. The second event was a report by Collins et al. 4 in 1969 that showed that simple cold storage preserved the organ, simplified the transportation, and facilitated the exchange of kidneys to improve tissue matching by widening the donor pool.
Over the past several decades, a dramatic improvement in kidney transplant survival has been achieved, leading to increasing demand for deceased donor organs. With a limited supply, transplant programmes are accepting kidneys from older donors and from donors following cardiac arrest. Recent interest in pulsatile preservation is motivated by efforts to improve renal allograft outcomes in spite of the increasing use of marginal donors. Nearly 50% of organs are now obtained from expanded criteria donors (ECDs) or donors after circulatory death (DCDs). Pulsatile perfusion requires a surgeon or technician to attach the renal arteries to a machine that pumps chilled preservation solution through the kidney in a recirculating fashion. The machine is programmed to maintain a set perfusion pressure or flow rate. In some cases, a technician will monitor these parameters and add medications to reduce the vascular resistance in the kidney. Generally, a kidney must be on the machine for ≥6 h to achieve the maximum benefits, such as reductions in perfusion pressures and levels of inflammatory cytokines. 5, 6 Although new pulsatile preservation units are highly portable and require only low levels of maintenance, they are rarely transported outside of the local organ procurement agency boundaries because of their expense.
In a recent study of the Scientific Registry of Transplant Recipients, Gill et al. 7 clearly show that use of machine preservation has increased in the past decade, with approximately 50% of organs from DCDs and ECDs being placed on pulsatile perfusion. The major strength of the analysis is the large cohort of patients (n = 94,709) from the USA. The multivariate analysis of cold ischaemia time and preservation method showed that kidneys from standard criteria donors (SCDs) with acute kidney injury or diabetes, as well as those who experienced trauma, seem to be selected for pulsatile perfusion. The authors demonstrate that the risk of delayed graft function (DGF) increases with prolonged cold ischaemia time and the relative risk of DGF is reduced by a statistically significant level for organs from SCDs, ECDs, and DCDs (all P <0.05) with pulsatile perfusion. The only exception is pulsatile perfusion does not decrease the risk of DGF for organs from ECDs with <6 h of cold ischaemia time (P >0.05).
Although large, the study has considerable limitations. The authors attempt to control for some of these with the multivariate analysis. They acknowledge that a retrospective analysis of registry data is not able to determine all of the factors that contributed to the decision to use pulsatile perfusion. 7 In particular, for the kidneys with cold ischaemia time of >24 h, perfusion parameters that include high renal resistance and biopsy results might have led to organ discard. These results can also influence the choice of recipient. The greatest limitation of the study by Gill and co-workers-in my opinion-is that the duration of DGF was not reported. 7 With the large number of patients in this study, a small difference in the need for dialysis in the first week after transplantation might be statistically significant, but clinically not that important if the long-term graft function and survival are the same.
In the current era of limited donor organ supply, we need to use all organs that will provide benefit to patients. That pulsatile perfusion can reduce DGF and, in many cases, has been associated with lower rates of rejection is encouraging. However, we need additional information regarding kidney function, rates of rejection, and 1-year graft survival to adequately determine the benefits of various new preservation techniques.
As transplant professionals, we must also be good stewards of our limited healthcare resources. Pulsatile perfusion substantially increases the cost of organ acquisition and the benefits of this additional cost might not be offset for many years. A limitation of this type of analysis is that pulsatile perfusion is used in a highly variable fashion. Only a few programmes keep the organ on the machine from the time of organ recovery until the time of preparation for transplantation. Instead, most centres use a combination of phases of cold storage and machine preservation. The optimal timing of pulsatile perfusion and the minimal time on the machine to achieve a reduction in DGF remain to be determined. In some cases, it might be better to minimize cold ischaemia Aaliya Landholt/iStock/Thinkstock www.nature.com/nrneph NEWS & VIEWS time than to 'pump' . To make true progress in the field, we need well-designed clinical trials with paired kidneys from individual donors and prospective recipient selection criteria. Unfortunately, only a few such trials have been conducted, some of which showed improved 1-year graft survival with pulsatile perfusion, 8 whereas others did not. 9 A thorough cost-benefit analysis will be very challenging. 
